Supplemental Figure 1: Patient Selection



Supplemental Table 1: Drug agents classified as immunotherapy according to the NCDB

|  |  |
| --- | --- |
| Checkpoint Inhibitors | AtezolizumabDurvalumabIpilimumabNivolumabPembrolizumab |
| Anti-VEGF/ Angiogenesis inhibitor | BevacizumabCyramza |
| EGFR Antibody | CetuximabDalotuzumabNecitumumabPanitumumab |
| Vaccines/ Adenoviral p53 Gene Therapy | BLP25BMS-936558CEA-VacEC-2101Dendritic cell-P53Egf Cancer VaccineFowlpox-CEA (6D)GVAX Lung Cancer VaccineINGN 201IV IL-2 Gene MedicineLung Cancer VaccineMGV VaccineMVA-Muc1-IL2P53 and RAS vaccineRAS 5-17 Peptide VaccineSB249553TBC-CEAVaccinia-CEA |
| Other | ThalidomideMatrix Metalloproteinease InhibitorAdvexinInterleukin-12ProMuneRC-3095TrastuzumabTriAbTriGemrecMAGE-A3+AS15 |

\* these agents are coded as approved for treatment of lung cancer, in clinical trial for lung cancer, or if lung is designated as a primary site of treatment according to the NCDB. Patients should be coded as yes to receiving immunotherapy (variable name RX\_SUMM\_IMMUNOTHERAPY) if they have been administered any of these agents variable.